Semanteon Capital Management LP Acquires New Position in AxoGen, Inc. (NASDAQ:AXGN)

Semanteon Capital Management LP purchased a new position in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 43,016 shares of the medical equipment provider's stock, valued at approximately $603,000. Semanteon Capital Management LP owned about 0.10% of AxoGen as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in shares of AxoGen during the 3rd quarter valued at $56,000. Koss Olinger Consulting LLC bought a new stake in AxoGen in the second quarter worth about $75,000. Lazard Asset Management LLC boosted its stake in AxoGen by 30.1% in the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider's stock valued at $93,000 after acquiring an additional 2,671 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of AxoGen during the 2nd quarter valued at approximately $125,000. Finally, BNP Paribas Financial Markets increased its stake in shares of AxoGen by 8.6% during the 1st quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider's stock worth $168,000 after purchasing an additional 1,651 shares during the last quarter. 80.29% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on AXGN shares. StockNews.com upgraded AxoGen from a "hold" rating to a "buy" rating in a research note on Tuesday, October 15th. Raymond James began coverage on AxoGen in a research note on Monday, July 1st. They set an "outperform" rating and a $13.00 price target for the company. Finally, JMP Securities upped their price objective on shares of AxoGen from $17.00 to $20.00 and gave the company a "market outperform" rating in a report on Friday, August 9th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, AxoGen has an average rating of "Buy" and an average target price of $15.00.

AxoGen Price Performance

Shares of AXGN stock traded up $0.02 during trading hours on Tuesday, reaching $13.96. The stock had a trading volume of 231,686 shares, compared to its average volume of 398,249. The stock's fifty day simple moving average is $13.55 and its 200 day simple moving average is $9.70. The company has a current ratio of 3.51, a quick ratio of 2.32 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $610.12 million, a PE ratio of -27.88 and a beta of 1.13. AxoGen, Inc. has a 12 month low of $3.45 and a 12 month high of $15.23.

AxoGen (NASDAQ:AXGN - Get Free Report) last posted its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. AxoGen had a negative return on equity of 17.30% and a negative net margin of 9.53%. The business had revenue of $47.91 million during the quarter, compared to analysts' expectations of $43.27 million. On average, equities research analysts predict that AxoGen, Inc. will post -0.33 EPS for the current year.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.